Incredibly excited to be recognized as one of @FortuneMagazine 2021 Best Workplaces in Biotechnology and Pharmaceuticals in the US. Our culture is grounded in the belief that success lies in the hands of individuals across every aspect of our company. fortune.com/best-workplaces-…

CEO Steven Nichtberger, MD is presenting at the H.C. Wainwright Global Life Sciences Conference. Watch the recorded fireside chat here. investors.cabalettabio.com/e…

CEO Steven Nichtberger, MD will participate in a cell therapy panel discussion beginning at 1:20 p.m. ET today at the Cowen & Co. 41st Annual Health Care Conference. #caart #celltherapy #autoimmunediseases

The 1st patient in the DesCAARTes™ Phase 1 clinical trial has been dosed, and the trial is recruiting patients with mucosal-dominant pemphigus vulgaris. We are thankful to @healourskin for giving us the opportunity to communicate our progress pemphigus.org/wp-content/upl…

Cabaletta Bio President and CEO Steven Nichtberger, MD, will present at the virtual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m. ET. #CAART #Autoimmune #CellTherapy #JPMHC21 investors.cabalettabio.com/e…

@CabalettaBio announces 1st patient dosed in landmark DesCAARTes™ trial of DSG3-CAART for treatment of patients with mucosal-dominant pemphigus vulgaris #CAART #autoimmune #CellTherapy investors.cabalettabio.com/n…

CEO Steven Nichtberger, MD is presenting today at 9:15 a.m. EST at the Evercore ISI 3rd Annual Virtual HealthCONx Conference. Listen to the live webcast here. investors.cabalettabio.com/e…

Philadelphia’s cell and gene therapy industry is at a tipping point and @CabalettaBio is excited to be part of the movement bizjournals.com/philadelphia…

CEO Steven Nichtberger, MD is presenting today at 11:30 a.m. EST at the Chardan 4th Annual Genetic Medicines Conference. Listen to the live webcast here. investors.cabalettabio.com/e…

CEO Steven Nichtberger, MD is presenting today at 8:30 a.m. EST at the Jefferies Virtual Cell Therapy Summit. Listen to the live webcast here. investors.cabalettabio.com/e…

Cabaletta Bio has been certified as a Great Place to Work. Our commitment to continuous self-improvement through a feedback culture with a drive toward equity, inclusion and high performing teams are core to who we are and aspire to be greatplacetowork.com/certifi…

CEO Steven Nichtberger, MD is presenting today at 4:30 p.m. EST at the H.C. Wainwright Global Investment Conference. Listen to the live webcast here. investors.cabalettabio.com/e…

CEO Steven Nichtberger, MD is presenting today at 3:00 p.m. EST at the Morgan Stanley Global Healthcare Conference. Listen to the live webcast here. investors.cabalettabio.com/e…

The DesCAARTes™ Phase 1 clinical trial is now recruiting patients with mucosal-dominant pemphigus vulgaris, and we are thankful to the @healourskin for letting us share our passion to discover and develop cures for patients with #autoimmune diseases pemphigus.org/wp-content/upl…

@CabalettaBio announces publication in the JCI of preclinical results for DSG3-CAART in #pemphigus vulgaris (PV), which supported the opening of the DesCAARTes Phase 1 clinical trial in patients with mucosal-dominant PV investors.cabalettabio.com/n…

CEO Steven Nichtberger, MD is presenting today at 11:30 a.m. EST at the Canaccord Genuity Growth Conference. Listen to the live webcast here. investors.cabalettabio.com/n…

CEO Steven Nichtberger, MD is presenting today at 8:35 a.m. EST at the Wedbush PacGrow Healthcare Virtual Conference. Listen to the live webcast here. investors.cabalettabio.com/n…

CEO Steven Nichtberger, M.D., is presenting today at 1:00 p.m. EST at the BTIG Virtual Biotechnology Conference. Listen to the live webcast here. investors.cabalettabio.com/n…

Cabaletta Bio today announced financial results for the second quarter ended June 30, 2020 and provided business update #CAART #autoimmune #celltherapy investors.cabalettabio.com/n…

CEO Steven Nichtberger, M.D., is presenting today at 3:30 p.m. EST at the Jefferies Virtual Healthcare Conference. Listen to the live webcast here. investors.cabalettabio.com/n…